AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KSEP 42 min read$AIM

AIM ImmunoTech Inc. (AIM): Entry into a Material Definitive Agreement

AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 31, 2026 through September 3, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of five exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (togethe

Original reporting
SEC EDGAR 8-K
Published Sep 4, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$AIM
Neutral
high confidence
Mentioned
$AIM
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AIMNeutralMed
01

Why it matters

The note conversion eliminates a liability and adds over 5 M shares, altering capital structure.

02

Market read

Primary corporate action for a micro‑cap biotech; modest trading relevance.

03

What to watch

Potential future financing needs if cash burn remains high.

Relevance 6/10Novelty 6/10Timing: filed Sep 4 2026

Background

SEC Form 8‑K disclosed AIM ImmunoTech's settlement of a 2024 promissory note via share exchange.

Company-level read

Ticker impact

$AIMNeutralHigh confidence
Context

AIM ImmunoTech converted a $1.224M promissory note into 5,065,840 common shares at $0.24 per share, fully satisfying the note.

Expected impact

Modest upward pressure as debt is eliminated, offset by dilution.

Evidence & confidence

Debt removal is positive, but issuance of over 5 M new shares may temper gains.

Market effects

Sector

Biotech financing trends may see more note‑to‑equity conversions.

Regional

Limited to U.S. micro‑cap market.

Global

Low; no broader market effect.

Counterpoint

What could challenge this read

The dilution could outweigh debt removal, pressuring the stock lower.

Key entities

  • company
    AIM ImmunoTech Inc.

    Issuer of the promissory note.

  • lender
    Streeterville Capital, LLC

    Counterparty in the exchange agreements.

Read at source← All news

Related articles

AUG 10
$AIMLow

AIM ImmunoTech Inc. (AIM): Results of Operations and Financial Condition

AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer Completed Enrollment and Ampligen Do

SEC EDGAR 8-K2 min
JUL 23
$AIMMedAI 8/10

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

AIM ImmunoTech said its Phase 2 pancreatic cancer trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) after FOLFIRINOX reached final patient enrollment ahead of schedule. The company expects to complete dosing and assess the primary Clinical Benefit Rate endpoint in December 2026, while continuing Phase 3 planning and expanding regulatory and IP efforts.

stocktwits.com4 min
JUL 9
$AIMMed

WA gold project Warrawoona fined $118,000 over threatened bat

Australia’s DCCEEW fined AIM Mining Corporation $118,000 for EPBC breaches at its Warrawoona Gold Project in WA’s Pilbara, tied to failure to protect the threatened Pilbara leaf-nosed bat. The regulator cited groundwater extraction over limits, missing species management steps, and reporting failures. AIM said it paid the fine. Calidus previously operated the project.

abc.net.au4 min
JUN 18
$AIMMed

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

AIM ImmunoTech said the final subject has received the first dose in its Phase 2 DURIPANC trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer. Primary endpoint analysis is expected to start in Dec. 2026, with topline results in Q1 2027; secondary endpoint analysis in June 2027. The primary endpoint is clinical benefit rate at 24 weeks.

manilatimes.net3 min